{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:05Z","timestamp":1789556585839,"version":"build-2803163510"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI191628"],"award-info":[{"award-number":["R21AI191628"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI191628"],"award-info":[{"award-number":["R21AI191628"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00931-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:50Z","timestamp":1789549130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases"],"prefix":"10.1007","volume":"204","author":[{"given":"Hasham","family":"Shafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Encinas-Basurto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Peter","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"931_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addr.2014.11.004","volume":"85","author":"T Velkov","year":"2015","unstructured":"Velkov T, Rahim NA, Zhou QT, Chan H-K, Li J (2015) Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv Drug Deliv Rev 85:65\u201382","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"931_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/17425247.2026.2631043","volume":"23","author":"N Islam","year":"2026","unstructured":"Islam N, Collet T (2026) Recent and future developments in inhaled formulations to overcome anti-bacterial drug resistance. Expert Opin Drug Deliv 23(5):877\u2013892","journal-title":"Expert Opin Drug Deliv"},{"key":"931_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.coph.2017.09.019","volume":"36","author":"KA Rodvold","year":"2017","unstructured":"Rodvold KA, Hope WW, Boyd SE (2017) Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol 36:114\u2013123","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"931_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jac\/dkg482","volume":"52","author":"A Barger","year":"2003","unstructured":"Barger A, Fuhst C, Wiedemann B (2003) Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 52(6):893\u2013898","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"931_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cpt.2190","volume":"109","author":"KJ Downes","year":"2021","unstructured":"Downes KJ, Goldman JL (2021) Too much of a good thing: defining antimicrobial therapeutic targets to minimize toxicity. Clin Pharmacol Ther 109(4):905\u2013917","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"931_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1517\/17425240903110710","volume":"6","author":"D Traini","year":"2009","unstructured":"Traini D, Young PM (2009) Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 6(9):897\u2013905","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"931_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discovery 6(1):67\u201374","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"931_CR8","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/09031936.00090314","volume":"44","author":"HA Tiddens","year":"2014","unstructured":"Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM (2014) Inhaled antibiotics: dry or wet? Eur Respir J 44(5):1308\u20131318","journal-title":"Eur Respir J"},{"issue":"6","key":"931_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/jamp.2023.29104.ajh","volume":"36","author":"AJ Hickey","year":"2023","unstructured":"Hickey AJ (2023) Dry powder inhalers: an overview. J Aerosol Med Pulm Drug Deliv 36(6):316\u2013323","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"931_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4187\/respcare.05500367","volume":"50","author":"JL Rau","year":"2005","unstructured":"Rau JL (2005) The inhalation of drugs: advantages and problems. Respir Care 50(3):367\u2013382","journal-title":"Respir Care"},{"issue":"1\u20132","key":"931_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.04.044","volume":"360","author":"N Islam","year":"2008","unstructured":"Islam N, Gladki E (2008) Dry powder inhalers (DPIs)\u2014a review of device reliability and innovation. Int J Pharm 360(1\u20132):1\u201311","journal-title":"Int J Pharm"},{"issue":"10","key":"931_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","volume":"7","author":"IF Laska","year":"2019","unstructured":"Laska IF, Crichton ML, Shoemark A, Chalmers JD (2019) The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med 7(10):855\u2013869","journal-title":"Lancet Respir Med"},{"issue":"3","key":"931_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/antibiotics12030484","volume":"12","author":"D Li","year":"2023","unstructured":"Li D, Schneider-Futschik EK (2023) Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis. Antibiotics 12(3):484","journal-title":"Antibiotics"},{"issue":"9","key":"931_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4187\/respcare.05501139","volume":"50","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ (2005) History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care 50(9):1139\u20131150","journal-title":"Respir Care"},{"issue":"3","key":"931_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","volume":"11","author":"BS Quon","year":"2014","unstructured":"Quon BS, Goss CH, Ramsey BW (2014) Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 11(3):425\u2013434","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"931_CR16","first-page":"447","volume":"3","author":"J Oxford","year":"2000","unstructured":"Oxford J (2000) Zanamivir (Glaxo Wellcome). IDrugs Invest Drugs J 3(4):447\u2013459","journal-title":"IDrugs Invest Drugs J"},{"issue":"4","key":"931_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/mp300043f","volume":"9","author":"RK Verma","year":"2012","unstructured":"Verma RK, Mukker JK, Singh RSP, Kumar K, Verma PRP, Misra A (2012) Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. Mol Pharm 9(4):1011\u20131016","journal-title":"Mol Pharm"},{"key":"931_CR18","doi-asserted-by":"publisher","first-page":"102081","DOI":"10.1016\/j.tube.2021.102081","volume":"128","author":"AK Singh","year":"2021","unstructured":"Singh AK, Verma RK, Mukker JK, Yadav AB, Muttil P, Sharma R et al (2021) Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month. Tuberculosis 128:102081","journal-title":"Tuberculosis"},{"issue":"4","key":"931_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1128\/AAC.01471-09","volume":"54","author":"L Garcia-Contreras","year":"2010","unstructured":"Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, VerBerkmoes JL et al (2010) Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 54(4):1436\u20131442","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"931_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","volume":"91","author":"A Misra","year":"2011","unstructured":"Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K et al (2011) Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91(1):71\u201381","journal-title":"Tuberculosis"},{"issue":"5","key":"931_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/ers.11.56","volume":"5","author":"MD Parkins","year":"2011","unstructured":"Parkins MD, Elborn JS (2011) Tobramycin Inhalation Powder\u2122: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 5(5):609\u2013622","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"931_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s41030-015-0007-6","volume":"1","author":"C Schwarz","year":"2015","unstructured":"Schwarz C (2015) Colobreathe\u00ae for the treatment of cystic fibrosis-associated pulmonary infections. Pulmonary Therapy 1(1):19\u201330","journal-title":"Pulmonary Therapy"},{"issue":"4","key":"931_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1208\/s12249-023-02559-y","volume":"24","author":"HW Chan","year":"2023","unstructured":"Chan HW, Chow S, Zhang X, Zhao Y, Tong HHY, Chow SF (2023) Inhalable nanoparticle-based dry powder formulations for respiratory diseases: challenges and strategies for translational research. AAPS PharmSciTech 24(4):98","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"931_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12249-020-01744-7","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang J, Peng Y, Xu H, Cui Z, Williams RO III (2020) The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech 21(6):225","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"931_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/02652048.2023.2175924","volume":"40","author":"SHY Chan","year":"2023","unstructured":"Chan SHY, Sheikh K, Zariwala MG, Somavarapu S (2023) Dry powder formulation of azithromycin for COVID-19 therapeutics. J Microencapsul 40(4):217\u2013232","journal-title":"J Microencapsul"},{"key":"931_CR26","doi-asserted-by":"publisher","first-page":"121688","DOI":"10.1016\/j.ijpharm.2022.121688","volume":"619","author":"AH Albariqi","year":"2022","unstructured":"Albariqi AH, Wang Y, Chang RYK, Quan DH, Wang X, Kalfas S et al (2022) Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment. Int J Pharm 619:121688","journal-title":"Int J Pharm"},{"issue":"7992","key":"931_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","volume":"624","author":"T Ye","year":"2023","unstructured":"Ye T, Jiao Z, Li X, He Z, Li Y, Yang F et al (2023) Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624(7992):630\u2013638","journal-title":"Nature"},{"issue":"1","key":"931_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/17425247.1.1.67","volume":"1","author":"HW Frijlink","year":"2004","unstructured":"Frijlink HW, De Boer A (2004) Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 1(1):67\u201386","journal-title":"Expert Opin Drug Deliv"},{"key":"931_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","volume":"75","author":"M Hoppentocht","year":"2014","unstructured":"Hoppentocht M, Hagedoorn P, Frijlink H, De Boer A (2014) Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev 75:18\u201331","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"931_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","volume":"406","author":"TC Carvalho","year":"2011","unstructured":"Carvalho TC, Peters JI, Williams RO III (2011) Influence of particle size on regional lung deposition\u2014what evidence is there? Int J Pharm 406(1\u20132):1\u201310","journal-title":"Int J Pharm"},{"issue":"3","key":"931_CR31","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","volume":"15","author":"YS Cheng","year":"2014","unstructured":"Cheng YS (2014) Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 15(3):630\u2013640","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"931_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1021\/mp4006563","volume":"11","author":"A Gupta","year":"2014","unstructured":"Gupta A, Pant G, Mitra K, Madan J, Chourasia MK, Misra A (2014) Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm 11(4):1201\u20131207","journal-title":"Mol Pharm"},{"issue":"6","key":"931_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1517\/17425247.2015.1039509","volume":"12","author":"W-H Lee","year":"2015","unstructured":"Lee W-H, Loo C-Y, Traini D, Young PM (2015) Nano-and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv 12(6):1009\u20131026","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"931_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/pharmaceutics13010031","volume":"13","author":"B Chaurasiya","year":"2020","unstructured":"Chaurasiya B, Zhao Y-Y (2020) Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics 13(1):31","journal-title":"Pharmaceutics"},{"issue":"2","key":"931_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40005-023-00635-w","volume":"54","author":"M-S Yang","year":"2024","unstructured":"Yang M-S, Kang J-H, Kim D-W, Park C-W (2024) Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery. J Pharm Invest 54(2):113\u2013130","journal-title":"J Pharm Invest"},{"key":"931_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jconrel.2020.07.002","volume":"325","author":"H Douafer","year":"2020","unstructured":"Douafer H, Andrieu V, Brunel JM (2020) Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases. J Control Release 325:276\u2013292","journal-title":"J Control Release"},{"key":"931_CR37","doi-asserted-by":"crossref","unstructured":"Hickey AJ, Mansour HM (2016) Delivery of drugs by the pulmonary route. In: Modern pharmaceutics, vol 2. CRC, pp 209\u2013238","DOI":"10.3109\/9781420065688-9"},{"issue":"1","key":"931_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Gokarn Y, Mitragotri S (2019) Non-invasive delivery strategies for biologics. Nat Rev Drug Discov 18(1):19\u201340","journal-title":"Nat Rev Drug Discov"},{"key":"931_CR39","unstructured":"Encinas-Basurto D, Shafi H, Chavan S, Verma K, Yadav C, Fox KAB et al (2026) Pulmonary barriers to targeted delivery. In: Harnessing endogenous mechanisms for targeted drug delivery. Elsevier, pp 111\u2013148"},{"issue":"5","key":"931_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/jamp.2024.27498.bp","volume":"37","author":"B Patel","year":"2024","unstructured":"Patel B, Gupta N, Ahsan F (2024) Barriers that inhaled particles encounter. J Aerosol Med Pulm Drug Deliv 37(5):299\u2013306","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"931_CR41","doi-asserted-by":"publisher","first-page":"16053","DOI":"10.1038\/npjpcrm.2016.53","volume":"26","author":"C Janson","year":"2016","unstructured":"Janson C, L\u00f6\u00f6f T, Telg G, Stratelis G, Nilsson F (2016) Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med 26(1):16053","journal-title":"NPJ Prim Care Respir Med"},{"issue":"5","key":"931_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nri3211","volume":"12","author":"L Ramakrishnan","year":"2012","unstructured":"Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12(5):352\u2013366","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"931_CR43","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1002\/jps.23705","volume":"102","author":"AJ Hickey","year":"2013","unstructured":"Hickey AJ, Misra A, Fourie PB (2013) Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J Pharm Sci 102(11):3900\u20133907","journal-title":"J Pharm Sci"},{"issue":"11","key":"931_CR44","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","volume":"26","author":"P Muttil","year":"2009","unstructured":"Muttil P, Wang C, Hickey AJ (2009) Inhaled drug delivery for tuberculosis therapy. Pharm Res 26(11):2401\u20132416","journal-title":"Pharm Res"},{"issue":"10","key":"931_CR45","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1023\/A:1012296604685","volume":"18","author":"R Sharma","year":"2001","unstructured":"Sharma R, Saxena D, Dwivedi AK, Misra A (2001) Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 18(10):1405\u20131410","journal-title":"Pharm Res"},{"issue":"2","key":"931_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","volume":"32","author":"P Muttil","year":"2007","unstructured":"Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A (2007) Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32(2):140\u2013150","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"931_CR47","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1128\/AAC.01897-12","volume":"57","author":"RK Verma","year":"2013","unstructured":"Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M et al (2013) Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother 57(2):1050\u20131052","journal-title":"Antimicrob Agents Chemother"},{"key":"931_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00099-19","author":"R Ranjan","year":"2019","unstructured":"Ranjan R, Srivastava A, Bharti R, Roy T, Verma S, Ray L et al (2019) Preclinical development of inhalable D-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00099-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"931_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1208\/s12249-023-02585-w","volume":"24","author":"S Verma","year":"2023","unstructured":"Verma S, Dal N-JK, Srivastava A, Bharti R, Siva Reddy D, Sofi HS et al (2023) Inhaled adjunct therapy with second-line drug candidates for dose reduction in chemotherapeutic regimens for multi-drug-resistant tuberculosis. AAPS PharmSciTech 24(5):130","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"931_CR50","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1128\/AAC.00153-08","volume":"52","author":"RK Verma","year":"2008","unstructured":"Verma RK, Kaur J, Kumar K, Yadav AB, Misra A (2008) Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 52(9):3195\u20133201","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"931_CR51","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1128\/AAC.02346-12","volume":"57","author":"AS Dharmadhikari","year":"2013","unstructured":"Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E, Phase (2013) Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 57(6):2613\u20132619","journal-title":"Antimicrob Agents Chemother"},{"key":"931_CR52","doi-asserted-by":"publisher","first-page":"102056","DOI":"10.1016\/j.pupt.2021.102056","volume":"70","author":"N Laohapojanart","year":"2021","unstructured":"Laohapojanart N, Ratanajamit C, Kawkitinarong K, Srichana T (2021) Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial. Pulm Pharmacol Ther 70:102056","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"931_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1517\/17425247.2015.1078309","volume":"13","author":"TD Sugianto","year":"2016","unstructured":"Sugianto TD, Chan H-K (2016) Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opin Drug Deliv 13(1):7\u201322","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"931_CR54","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4187\/respcare.09540658","volume":"54","author":"DE Geller","year":"2009","unstructured":"Geller DE (2009) Aerosol antibiotics in cystic fibrosis. Respir Care 54(5):658\u2013670","journal-title":"Respir Care"},{"issue":"3","key":"931_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/jamp.2017.1415","volume":"31","author":"R Dhand","year":"2018","unstructured":"Dhand R (2018) The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 31(3):121\u2013138","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"130","key":"931_CR56","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1183\/09059180.00001513","volume":"22","author":"L Uttley","year":"2013","unstructured":"Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K et al (2013) Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. Eur Respir Rev 22(130):476\u2013486","journal-title":"Eur Respir Rev"},{"issue":"5","key":"931_CR57","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/ers.12.45","volume":"6","author":"PE Grgurich","year":"2012","unstructured":"Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE (2012) Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 6(5):533\u2013555","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"931_CR58","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1164\/rccm.202402-0437CP","volume":"210","author":"S Ehrmann","year":"2024","unstructured":"Ehrmann S, Barbier F, Li J (2024) Aerosolized antibiotic therapy in mechanically ventilated patients. Am J Respir Crit Care Med 210(6):730\u2013736","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"931_CR59","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/CCM.0000000000006323","volume":"52","author":"J Li","year":"2024","unstructured":"Li J, Lyu S, Luo J, Liu P, Albuainain FA, Alamoudi OA et al (2024) Prophylactic antibiotics delivered via the respiratory tract to reduce ventilator-associated pneumonia: a systematic review, network meta-analysis, and trial sequential analysis of randomized controlled trials. Crit Care Med 52(10):1612\u20131623","journal-title":"Crit Care Med"},{"key":"931_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcrc.2021.06.004","volume":"65","author":"R Tang","year":"2021","unstructured":"Tang R, Luo R, Wu B, Wang F, Song H, Chen X (2021) Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials. J Crit Care 65:133\u2013139","journal-title":"J Crit Care"},{"issue":"5","key":"931_CR61","doi-asserted-by":"publisher","first-page":"e093868","DOI":"10.1136\/bmjopen-2024-093868","volume":"15","author":"X Yuan","year":"2025","unstructured":"Yuan X, Feng Y, Wan J, Zhang S, Bao Q, Liu X et al (2025) Effect of nebulised inhalation of antibiotics on preventing ventilator-associated pneumonia in critically ill patients: a systematic review and meta-analysis. BMJ open 15(5):e093868","journal-title":"BMJ open"},{"issue":"3","key":"931_CR62","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cid\/ciw726","volume":"64","author":"LM Daniels","year":"2017","unstructured":"Daniels LM, Juliano J, Marx A, Weber DJ (2017) Inhaled antibiotics for hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 64(3):386\u2013387","journal-title":"Clin Infect Dis"},{"key":"931_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00973-17","author":"Y-W Lin","year":"2017","unstructured":"Lin Y-W, Zhou QT, Hu Y, Onufrak NJ, Sun S, Wang J et al (2017) Pulmonary pharmacokinetics of colistin following administration of dry powder aerosols in rats. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00973-17","journal-title":"Antimicrob Agents Chemother"},{"key":"931_CR64","doi-asserted-by":"publisher","unstructured":"Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E et al (2018) RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 51(1) : 1702053  https:\/\/doi.org\/10.1183\/13993003.02053-2017","DOI":"10.1183\/13993003.02053-2017"},{"key":"931_CR65","doi-asserted-by":"publisher","unstructured":"De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E et al (2018) RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 51(1); 1702052 https:\/\/doi.org\/10.1183\/13993003.02052-2017","DOI":"10.1183\/13993003.02052-2017"},{"key":"931_CR66","unstructured":"Manzanedo D, Brande M, Kramer SR, Yee LW, DeHaan WH, Clarke RW et al (2012) Formulation characterization of a novel levofloxacin pulmonary dry powder drug delivery technology. In: Proceedings of the respiratory drug delivery, pp 713\u2013716"},{"key":"931_CR67","doi-asserted-by":"publisher","unstructured":"Dibaei M, Gholami M, Lavasani H, Sheikholesalmi B, Toliyat T, Barazesh A et al (2026) Drug disposition study on a levofloxacin dry powder formulation using the isolated perfused lung in rats. Sci Rep 16, 12931. https:\/\/doi.org\/10.1038\/s41598-026-38890-0","DOI":"10.1038\/s41598-026-38890-0"},{"issue":"9","key":"931_CR68","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","volume":"2","author":"AF Barker","year":"2014","unstructured":"Barker AF, O\u2019Donnell AE, Flume P, Thompson PJ, Ruzi JD, De Gracia J et al (2014) Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2(9):738\u2013749","journal-title":"Lancet Respir Med"},{"issue":"2","key":"931_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","volume":"185","author":"BC Trapnell","year":"2012","unstructured":"Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M et al (2012) Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 185(2):171\u2013178","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"931_CR70","doi-asserted-by":"publisher","first-page":"01776","DOI":"10.1128\/aac","volume":"64","author":"G Waterer","year":"2020","unstructured":"Waterer G, Lord J, Hofmann T, Jouhikainen T, Phase I (2020) dose-escalating study of the safety and pharmacokinetics of inhaled dry-powder vancomycin (AeroVanc) in volunteers and patients with cystic fibrosis: a new approach to therapy for methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 64(3):01776\u201301719. https:\/\/doi.org\/10.1128\/aac","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"931_CR71","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/antibiotics11111527","volume":"11","author":"SV Valiulin","year":"2022","unstructured":"Valiulin SV, Onischuk AA, Baklanov AM, Dubtsov SN, Dultseva GG, An\u2019kov SV et al (2022) Studies of the specific activity of aerosolized isoniazid against tuberculosis in a mouse model. Antibiotics 11(11):1527","journal-title":"Antibiotics"},{"issue":"9","key":"931_CR72","doi-asserted-by":"publisher","first-page":"e00186","DOI":"10.1128\/aac.00186-22","volume":"66","author":"AD Brunaugh","year":"2022","unstructured":"Brunaugh AD, Walz A, Warnken Z, Pearce C, Munoz Gutierrez J, Koleng JJ et al (2022) Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB\/c mice with chronic Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 66(9):e00186\u2013e00122","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"931_CR73","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.3390\/pharmaceutics14122646","volume":"14","author":"M Zhu","year":"2022","unstructured":"Zhu M, Zhang D, Zhang L, Zhao L, Xu L, Wang B et al (2022) Spray-dried inhalable powder formulations of gentamicin designed for pneumonic plague therapy in a mouse model. Pharmaceutics 14(12):2646","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"931_CR74","first-page":"205","volume":"395","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Wang X, Lin X, Liu X, Tian B, Tang X (2010) High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 395(1\u20132):205\u2013214","journal-title":"Int J Pharm"},{"issue":"2","key":"931_CR75","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/v17020252","volume":"17","author":"T Saha","year":"2025","unstructured":"Saha T, Masum ZU, Biswas A, Mou MA, Ahmed S, Saha T (2025) Inhaled dry powder of antiviral agents: a promising approach to treating respiratory viral pathogens. Viruses 17(2):252","journal-title":"Viruses"},{"key":"931_CR76","doi-asserted-by":"publisher","first-page":"102170","DOI":"10.1016\/j.pupt.2022.102170","volume":"77","author":"N Nainwal","year":"2022","unstructured":"Nainwal N (2022) Treatment of respiratory viral infections through inhalation therapeutics: challenges and opportunities. Pulm Pharmacol Ther 77:102170","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"931_CR77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/jinf.1999.0602","volume":"40","author":"M M\u00e4kel\u00e4","year":"2000","unstructured":"M\u00e4kel\u00e4 M, Pauksens K, Rostila Taa, Fleming D, Man C, Keene O et al (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40(1):42\u201348","journal-title":"J Infect"},{"issue":"1","key":"931_CR78","doi-asserted-by":"publisher","first-page":"01722","DOI":"10.1128\/aac","volume":"62","author":"K Toyama","year":"2018","unstructured":"Toyama K, Furuie H, Ishizuka H (2018) Intrapulmonary pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single nebulized administration of laninamivir octanoate in healthy Japanese subjects. Antimicrob Agents Chemother 62(1):01722\u201301717. https:\/\/doi.org\/10.1128\/aac","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"931_CR79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/pharmaceutics18020242","volume":"18","author":"BJ Anaya","year":"2026","unstructured":"Anaya BJ, Osorio-Vargas E, Monterrosa-Moreno S, Tirado DF, Gonz\u00e1lez-Burgos E, Serrano DR (2026) Pulmonary drug delivery for infectious diseases: cutting-edge formulations and manufacturing technologies. Pharmaceutics 18(2):242","journal-title":"Pharmaceutics"},{"issue":"11","key":"931_CR80","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/pharmaceutics12111002","volume":"12","author":"S Sahakijpijarn","year":"2020","unstructured":"Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams RO (2020) Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics 12(11):1002","journal-title":"Pharmaceutics"},{"key":"931_CR81","first-page":"100073","volume":"3","author":"S Sahakijpijarn","year":"2021","unstructured":"Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ et al (2021) In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. Int J Pharm X 3:100073","journal-title":"Int J Pharm X"},{"key":"931_CR82","doi-asserted-by":"publisher","unstructured":"Zhang X, Wang B, Xu L, Zhao L, Zhang L, Bei Z et al (2025) Spray-dried inhalable favipiravir dry powder formulation for influenza therapy: preparation and in vivo evaluation. Curr Drug Deliv, 23(4), 462-474. https:\/\/doi.org\/10.2174\/0115672018351326250306040551","DOI":"10.2174\/0115672018351326250306040551"},{"issue":"11","key":"931_CR83","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s11095-024-03782-3","volume":"41","author":"VSR Devireddy","year":"2024","unstructured":"Devireddy VSR, Shafi H, Verma S, Singh S, Chakradhar J, Kothuri N et al (2024) Comparative preclinical pharmacokinetics and disposition of favipiravir following pulmonary and oral administration as potential adjunct therapy against airborne RNA viruses. Pharm Res 41(11):2189\u20132198","journal-title":"Pharm Res"},{"issue":"5","key":"931_CR84","doi-asserted-by":"publisher","first-page":"02267","DOI":"10.1128\/aac","volume":"64","author":"EF Dumont","year":"2020","unstructured":"Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van Den Berg F et al (2020) A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study. Antimicrob Agents Chemother 64(5):02267\u201302219. https:\/\/doi.org\/10.1128\/aac","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"931_CR85","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3109\/10717544.2013.863526","volume":"22","author":"Y Tang","year":"2015","unstructured":"Tang Y, Zhang H, Lu X, Jiang L, Xi X, Liu J et al (2015) Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. Drug Deliv 22(5):608\u2013618","journal-title":"Drug Deliv"},{"issue":"7","key":"931_CR86","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17425247.2022.2084530","volume":"19","author":"K Ito","year":"2022","unstructured":"Ito K (2022) Inhaled antifungal therapy: benefits, challenges, and clinical applications. Expert Opin Drug Deliv 19(7):755\u2013769","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"931_CR87","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.2174\/1381612826666210101153547","volume":"27","author":"Q Liao","year":"2021","unstructured":"Liao Q, Lam JK (2021) Inhaled antifungal agents for the treatment and prophylaxis of pulmonary mycoses. Curr Pharm Des 27(12):1453\u20131468","journal-title":"Curr Pharm Des"},{"key":"931_CR88","doi-asserted-by":"crossref","unstructured":"Ito K (2025) Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections? Taylor & Francis, pp 537\u2013540","DOI":"10.1080\/14787210.2025.2530624"},{"key":"931_CR89","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.pupt.2023.102233","volume":"82","author":"H Hagiya","year":"2023","unstructured":"Hagiya H, Nishimura Y, Otsuka F (2023) Safety and usefulness of nebulized liposomal amphotericin B: systematic scoping review. Pulm Pharmacol Ther 82:102233","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"931_CR90","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/jof6040373","volume":"6","author":"A Murray","year":"2020","unstructured":"Murray A, Cass L, Ito K, Pagani N, Armstrong-James D, Dalal P et al (2020) PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections. J Fungi 6(4):373","journal-title":"J Fungi"},{"issue":"4","key":"931_CR91","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bcp.14166","volume":"86","author":"DL Hava","year":"2020","unstructured":"Hava DL, Tan L, Johnson P, Curran AK, Perry J, Kramer S et al (2020) A phase 1\/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. Br J Clin Pharmacol 86(4):723\u2013733","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"931_CR92","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1517\/17425247.2016.1114603","volume":"13","author":"S Arora","year":"2016","unstructured":"Arora S, Haghi M, Young PM, Kappl M, Traini D, Jain S (2016) Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. Expert Opin Drug Deliv 13(2):183\u2013193","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"931_CR93","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ejpb.2012.04.019","volume":"81","author":"NA Beinborn","year":"2012","unstructured":"Beinborn NA, Du J, Wiederhold NP, Smyth HD, Williams RO III (2012) Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur J Pharm Biopharm 81(3):600\u2013608","journal-title":"Eur J Pharm Biopharm"},{"key":"931_CR94","doi-asserted-by":"publisher","first-page":"124938","DOI":"10.1016\/j.ijpharm.2024.124938","volume":"668","author":"X Li","year":"2025","unstructured":"Li X, Wang Q, Huang J, Yue X, Zhang X, Fan X et al (2025) Posaconazole nanocrystals dry powder inhalers for the local treatment of invasive pulmonary aspergillosis. Int J Pharm 668:124938","journal-title":"Int J Pharm"},{"issue":"12","key":"931_CR95","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/pharmaceutics14122632","volume":"14","author":"SR Pardeshi","year":"2022","unstructured":"Pardeshi SR, Kole EB, Kapare HS, Chandankar SM, Shinde PJ, Boisa GS et al (2022) Progress on thin film freezing technology for dry powder inhalation formulations. Pharmaceutics 14(12):2632","journal-title":"Pharmaceutics"},{"issue":"11","key":"931_CR96","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/pharmaceutics15112601","volume":"15","author":"SS Celi","year":"2023","unstructured":"Celi SS, Fern\u00e1ndez-Garc\u00eda R, Afonso-Urich AI, Ballesteros MP, Healy AM, Serrano DR (2023) Co-delivery of a high dose of amphotericin B and Itraconazole by means of a dry powder inhaler formulation for the treatment of severe fungal pulmonary infections. Pharmaceutics 15(11):2601","journal-title":"Pharmaceutics"},{"issue":"5","key":"931_CR97","doi-asserted-by":"publisher","first-page":"103954","DOI":"10.1016\/j.drudis.2024.103954","volume":"29","author":"S Dhoble","year":"2024","unstructured":"Dhoble S, Kapse A, Ghegade V, Chogale M, Ghodake V, Patravale V et al (2024) Design, development, and technical considerations for dry powder inhaler devices. Drug Discovery Today 29(5):103954","journal-title":"Drug Discovery Today"},{"issue":"12","key":"931_CR98","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s11095-022-03363-2","volume":"39","author":"RYK Chang","year":"2022","unstructured":"Chang RYK, Chan H-K (2022) Advancements in particle engineering for inhalation delivery of small molecules and biotherapeutics. Pharm Res 39(12):3047\u20133061","journal-title":"Pharm Res"},{"issue":"2","key":"931_CR99","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/jamp.2024.29109.davm","volume":"37","author":"DA Morton","year":"2024","unstructured":"Morton DA, Barling D (2024) Developing dry powder inhaler formulations. J Aerosol Med Pulm Drug Deliv 37(2):90\u201399","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"27","key":"931_CR100","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.2174\/1381612821666150820111134","volume":"21","author":"Y-W Lin","year":"2015","unstructured":"Lin Y-W, Wong J, Qu L, Chan H-K, Zhou Q (2015) Powder production and particle engineering for dry powder inhaler formulations. Curr Pharm Des 21(27):3902\u20133916","journal-title":"Curr Pharm Des"},{"issue":"1","key":"931_CR101","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ijpharm.2018.07.007","volume":"548","author":"S Yeung","year":"2018","unstructured":"Yeung S, Traini D, Lewis D, Young PM (2018) Dosing challenges in respiratory therapies. Int J Pharm 548(1):659\u2013671","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"931_CR102","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijpharm.2018.07.050","volume":"549","author":"MK Hatipoglu","year":"2018","unstructured":"Hatipoglu MK, Hickey AJ, Garcia-Contreras L (2018) Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Int J Pharm 549(1\u20132):306\u2013316","journal-title":"Int J Pharm"},{"issue":"1","key":"931_CR103","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijpharm.2018.07.008","volume":"548","author":"I Sibum","year":"2018","unstructured":"Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F (2018) Challenges for pulmonary delivery of high powder doses. Int J Pharm 548(1):325\u2013336","journal-title":"Int J Pharm"},{"key":"931_CR104","doi-asserted-by":"publisher","first-page":"106158","DOI":"10.1016\/j.ejps.2022.106158","volume":"172","author":"R Scherliess","year":"2022","unstructured":"Scherliess R, Bock S, Bungert N, Neustock A, Valentin L (2022) Particle engineering in dry powders for inhalation. Eur J Pharm Sci 172:106158","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"931_CR105","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/pharmaceutics17030359","volume":"17","author":"HA Al-Assaf","year":"2025","unstructured":"Al-Assaf HA, Papadimitriou SA, Rahman A, Badhan R, Mohammed AR (2025) Advanced manufacturing methods for high-dose inhalable powders. Pharmaceutics 17(3):359","journal-title":"Pharmaceutics"},{"issue":"26","key":"931_CR106","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1002\/anie.201209145","volume":"52","author":"J Xu","year":"2013","unstructured":"Xu J, Wong DH, Byrne JD, Chen K, Bowerman C, DeSimone JM (2013) Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed 52(26):6580\u20136589","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"931_CR107","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/jamp.2010.0855","volume":"24","author":"DE Geller","year":"2011","unstructured":"Geller DE, Weers J, Heuerding S (2011) Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere\u2122 technology. J Aerosol Med Pulm Drug Deliv 24(4):175\u2013182","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"931_CR108","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4155\/tde.14.3","volume":"5","author":"J Weers","year":"2014","unstructured":"Weers J, Tarara T (2014) The PulmoSphere\u2122 platform for pulmonary drug delivery. Ther Deliv 5(3):277\u2013295","journal-title":"Ther Deliv"},{"key":"931_CR109","doi-asserted-by":"publisher","first-page":"176","DOI":"10.14356\/kona.2022010","volume":"39","author":"S Hufnagel","year":"2022","unstructured":"Hufnagel S, Sahakijpijarn S, Moon C, Cui Z, Williams RO III (2022) The development of thin-film freezing and its application to improve delivery of biologics as dry powder aerosols. Kona Powder Part J 39:176\u2013192","journal-title":"Kona Powder Part J"},{"issue":"3","key":"931_CR110","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/10837450.2021.2021941","volume":"27","author":"M Rostamnezhad","year":"2022","unstructured":"Rostamnezhad M, Jafari H, Moradikhah F, Bahrainian S, Faghihi H, Khalvati R et al (2022) Spray freeze-drying for inhalation application: process and formulation variables. Pharm Dev Technol 27(3):251\u2013267","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"931_CR111","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43246-025-00913-0","volume":"6","author":"M Wostry","year":"2025","unstructured":"Wostry M, Berkes A, Kiefer P, Wegener M, Scherlie\u00df R (2025) Aerodynamic performance of tailored microparticles as carriers in dry powder inhaler formulations made by multi-focus multi-photon 3D laser printing. Commun Mater 6(1):184","journal-title":"Commun Mater"},{"issue":"3","key":"931_CR112","doi-asserted-by":"publisher","first-page":"e12119","DOI":"10.1002\/pul2.12119","volume":"12","author":"NS Hill","year":"2022","unstructured":"Hill NS, Feldman JP, Sahay S, Benza RL, Preston IR, Badesch D et al (2022) INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulmonary circulation 12(3):e12119","journal-title":"Pulmonary circulation"},{"issue":"7","key":"931_CR113","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/pharmaceutics17070893","volume":"17","author":"DE Mahmoud","year":"2025","unstructured":"Mahmoud DE, Hosseini SH, Rathore HA, Alkilany AM, Heise A, Elhissi A (2025) Inhalable nanotechnology-based drug delivery systems for the treatment of inflammatory lung diseases. Pharmaceutics 17(7):893","journal-title":"Pharmaceutics"},{"issue":"21","key":"931_CR114","doi-asserted-by":"publisher","first-page":"e71191","DOI":"10.1096\/fj.202502624R","volume":"39","author":"Y Fan","year":"2025","unstructured":"Fan Y, Zhou Y, Zhao J, Zhao Y (2025) Advances in inhaled nanoparticle drug delivery for pulmonary disease management. FASEB J 39(21):e71191","journal-title":"FASEB J"},{"key":"931_CR115","doi-asserted-by":"publisher","unstructured":"He N, Dong K, Lee W, Bach H (2026) Precision nanomedicine against pulmonary tuberculosis: the role of lipid-based drug delivery systems. Nanomedicine, 21(5), 725\u2013743. https:\/\/doi.org\/10.1080\/17435889.2026.2624741","DOI":"10.1080\/17435889.2026.2624741"},{"key":"931_CR116","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","volume":"219","author":"A Kuzmov","year":"2015","unstructured":"Kuzmov A, Minko T (2015) Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 219:500\u2013518","journal-title":"J Control Release"},{"issue":"3","key":"931_CR117","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/pharmaceutics16030347","volume":"16","author":"G Costabile","year":"2024","unstructured":"Costabile G, Conte G, Brusco S, Savadi P, Miro A, Quaglia F et al (2024) State-of-the-art review on inhalable lipid and polymer nanocarriers: design and development perspectives. Pharmaceutics 16(3):347","journal-title":"Pharmaceutics"},{"key":"931_CR118","doi-asserted-by":"publisher","first-page":"114527","DOI":"10.1016\/j.addr.2022.114527","volume":"189","author":"GA Hebbink","year":"2022","unstructured":"Hebbink GA, Jaspers M, Peters HJ, Dickhoff BH (2022) Recent developments in lactose blend formulations for carrier-based dry powder inhalation. Adv Drug Deliv Rev 189:114527","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"931_CR119","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/pharmaceutics17010096","volume":"17","author":"T Mehta","year":"2025","unstructured":"Mehta T, Najafian S, Patel K, Lacombe J, Chaudhuri B (2025) Optimization of carrier-based dry powder inhaler performance: a review. Pharmaceutics 17(1):96","journal-title":"Pharmaceutics"},{"issue":"4","key":"931_CR120","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s13346-021-01011-7","volume":"11","author":"D Thiyagarajan","year":"2021","unstructured":"Thiyagarajan D, Huck B, Nothdurft B, Koch M, Rudolph D, Rutschmann M et al (2021) Spray-dried lactose-leucine microparticles for pulmonary delivery of antimycobacterial nanopharmaceuticals. Drug Deliv Transl Res 11(4):1766\u20131778","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"931_CR121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.rmed.2007.07.031","volume":"102","author":"J Virchow","year":"2008","unstructured":"Virchow J, Crompton G, Dal Negro R, Pedersen S, Magnan A, Seidenberg J et al (2008) Importance of inhaler devices in the management of airway disease. Respir Med 102(1):10\u201319","journal-title":"Respir Med"},{"issue":"1","key":"931_CR122","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/pharmaceutics17010111","volume":"17","author":"YH Dallal Bashi","year":"2025","unstructured":"Dallal Bashi YH, Mairs R, Murtadha R, Kett V (2025) Pulmonary delivery of antibiotics to the lungs: current state and future prospects. Pharmaceutics 17(1):111","journal-title":"Pharmaceutics"},{"issue":"6","key":"931_CR123","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/17425247.2015.977783","volume":"12","author":"P Muralidharan","year":"2015","unstructured":"Muralidharan P, Hayes D Jr, Mansour HM (2015) Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opin Drug Deliv 12(6):947\u2013962","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"931_CR124","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41533-022-00318-3","volume":"32","author":"MT Leving","year":"2022","unstructured":"Leving MT, Bosnic-Anticevich S, van Cooten J, de Sousa JC, Cvetkovski B, Dekhuijzen R et al (2022) Clinical recommendations for dry powder inhaler use in the management of COPD in primary care. NPJ Prim Care Respir Med 32(1):59","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1","key":"931_CR125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1586\/17476348.2014.854168","volume":"8","author":"S Salvi","year":"2014","unstructured":"Salvi S, Gogtay J, Aggarwal B (2014) Use of breath-actuated inhalers in patients with asthma and COPD\u2013an advance in inhalational therapy: a systematic review. Expert Rev Respir Med 8(1):89\u201399","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"931_CR126","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.4187\/respcare.05501331","volume":"50","author":"R Dhand","year":"2005","unstructured":"Dhand R (2005) Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir Care 50(10):1331\u20131345","journal-title":"Respir Care"},{"key":"931_CR127","doi-asserted-by":"crossref","unstructured":"Viswalingam V, Kumar D (2025) Advancements in smart inhaler technology for enhancing chronic obstructive pulmonary disease care. In: Advanced drug delivery systems in management of chronic obstructive pulmonary disease. CRC, pp 55\u201377","DOI":"10.1201\/9781003498926-5"},{"key":"931_CR128","doi-asserted-by":"publisher","first-page":"114580","DOI":"10.1016\/j.addr.2022.114580","volume":"191","author":"S H\u00e4u\u00dfermann","year":"2022","unstructured":"H\u00e4u\u00dfermann S, Arendsen LJ, Pritchard JN (2022) Smart dry powder inhalers and intelligent adherence management. Adv Drug Deliv Rev 191:114580","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00931-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:03:06Z","timestamp":1789552986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00931-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00931-w","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"5 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}